切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2017, Vol. 06 ›› Issue (03) : 216 -221. doi: 10.3877/cma.j.issn.2095-3232.2017.03.015

所属专题: 文献

临床研究

全脾切除术与部分脾切除术对门静脉高压症脾功能亢进患者免疫功能影响的比较
王永军1, 罗大勇1,(), 李恒1, 张伟1, 秦一雨2, 罗志梅2   
  1. 1. 236015 安徽省阜阳市第二人民医院普通外科
    2. 224005 江苏省盐城卫生职业技术学院科技处
  • 收稿日期:2017-01-10 出版日期:2017-06-10
  • 通信作者: 罗大勇
  • 基金资助:
    中国肝炎防治基金会王宝恩肝纤维化研究基金(XJS201311)

Comparison of effects on immune function of patients with portal hypertension and hypersplenism between total splenectomy and partial splenectomy

Yongjun Wang1, Dayong Luo1,(), Heng Li1, Wei Zhang1, Yiyu Qin2, Zhimei Luo2   

  1. 1. Department of General Surgery, the Second People's Hospital of Fuyang, Fuyang 236015, China
    2. Science and Technology Office, Jiangsu Vocational College of Medicine, Yancheng 224005, China
  • Received:2017-01-10 Published:2017-06-10
  • Corresponding author: Dayong Luo
  • About author:
    Corresponding author: Luo Dayong, Email:
引用本文:

王永军, 罗大勇, 李恒, 张伟, 秦一雨, 罗志梅. 全脾切除术与部分脾切除术对门静脉高压症脾功能亢进患者免疫功能影响的比较[J/OL]. 中华肝脏外科手术学电子杂志, 2017, 06(03): 216-221.

Yongjun Wang, Dayong Luo, Heng Li, Wei Zhang, Yiyu Qin, Zhimei Luo. Comparison of effects on immune function of patients with portal hypertension and hypersplenism between total splenectomy and partial splenectomy[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2017, 06(03): 216-221.

目的

探讨全脾切除术与部分脾切除术对肝硬化合并门静脉高压症脾功能亢进(脾亢)患者免疫功能的影响。

方法

回顾性分析2012年9月至2015年10月安徽省阜阳市第二人民医院收治的142例肝硬化合并门静脉高压症脾亢患者临床资料。其中男96例,女46例;年龄35~68岁,中位年龄53岁。患者均签署知情同意书,符合医学伦理学规定。根据术式不同将患者分为贲门周围血管离断术+全脾切除术组(全脾切除术组,85例)和贲门周围血管离断术+部分脾切除术(部分脾切除术组,57例)。两组患者围手术期指标比较采用t检验,术后并发症发生率比较采用χ2检验。

结果

术后2个月全脾切除术组IL-1、IL-2、IL-6、TGF-β、TNF-α水平分别为(37.3±2.5)、(35.5±1.0)、(47.7±2.6)、(54.6±1.2)、(25.3±1.1)μg/L,明显低于部分脾切除术组的(45.2±0.7)、(47.7±2.3)、(57.9±5.6)、(67.6±1.2)、(31.5±1.6) μg/L,而IgM水平(2.15±0.04)g/L明显高于部分脾切除术组的(1.86±0.03)g/L(t=-7.65,-7.63,-7.78,-10.12,-8.34,3.55;P<0.05)。部分脾切除术组上消化道出血及腹腔内出血发生率为25%(14/57),明显高于全脾切除术组的8%(7/85) (χ2=7.541,P<0.05)。

结论

对于肝硬化合并门静脉高压症脾亢患者,与部分脾切除术相比,全脾切除术后患者机体免疫功能可能恢复更快,其技术更为安全、成熟、有效。

Objective

To compare the effects on the immune function of patients with liver cirrhosis complicated with portal hypertension and hypersplenism between total splenectomy and partial splenectomy.

Methods

Clinical data of 142 patients with liver cirrhosis complicated with portal hypertension and hypersplenism who were admitted to the Second People's Hospital of Fuyang between September 2012 and October 2015 were retrospectively analyzed. Among them, 96 cases were males and 46 females, aged 35-68 years old with a median age of 53 years old. The informed consents of all patients were obtained and the local ethical committee approval was received. According to the surgical procedures, the patients were divided the pericardial devascularization + total splenectomy group (total splenectomy group, n=85) and pericardial devascularization + partial splenectomy group (partial splenectomy group, n=57). The perioperative indexes between two groups were compared using t test. The incidence of postoperative complications was compared using Chi-square test.

Results

The IL-1, IL-2, IL-6, TGF-β and TNF-α level at postoperative 2 months in the total splenectomy group was respectively (37.3±2.5), (35.5±1.0), (47.7±2.6), (54.6±1.2) and (25.3±1.1) μg/L, significantly lower than (45.2±0.7), (47.7±2.3), (57.9±5.6), (67.6±1.2) and (31.5±1.6) μg/L in the partial splenectomy group, whereas the IgM level was (2.15±0.04) g/L in the total splenectomy group, significantly higher than (1.86±0.03) g/L in the partial splenectomy group (t=-7.65, -7.63, -7.78, -10.12, -8.34, 3.55; P<0.05). The incidence of upper gastrointestinal and intraperitoneal hemorrhage in the partial splenectomy group was 25% (14/57), significantly higher than 8% (7/85) in the total splenectomy group (χ2=7.541, P<0.05).

Conclusions

For the patients with liver cirrhosis complicated with portal hypertension and hypersplenism, the immune function of the patients with total splenectomy may recover faster than the patients with partial splenectomy, and the techniques of total splenectomy are safer and more mature and efficacious.

表1 全脾切除术组和部分脾切除术组患者术前一般资料比较
图1 全脾切除术和部分脾切除术手术过程
表2 全脾切除术组和部分脾切除术组患者围手术期血常规指标水平变化(±s
表3 全脾切除术组和部分脾切除术组患者围手术期肝功能指标水平变化(±s
表4 全脾切除术组和部分脾切除术组患者围手术期免疫球蛋白水平变化(g/L,±s
表5 全脾切除术组和部分脾切除术组患者围手术期炎症和细胞因子水平变化(μg/L,±s
表6 全脾切除术组和部分脾切除术组患者术后并发症(例)
[1]
Liberal R, Grant CR. Cirrhosis and autoimmune liver disease: current understanding[J]. World J Hepatol, 2016, 8(28):1157-1168.
[2]
Licinio R, Losurdo G, Carparelli S, et al. Helicobacter pylori, liver cirrhosis, and portal hypertension: an updated appraisal[J]. Immunopharmacol Immunotoxicol, 2016, 38(6): 408-413.
[3]
Watson GA, Abu-Shanab A, O'Donohoe RL, et al. Enteroscopic management of ectopic varices in a patient with liver cirrhosis and portal hypertension[J]. Case Reports Hepatol, 2016: 2018642.
[4]
Ferrarese A, Zanetto A, Germani G, et al. Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension[J]. World J Hepatol, 2016, 8(24):1012-1018.
[5]
Wang DQ, Carey MC. Susceptibility to murine cholesterol gallstone formation is not affected by partial disruption of the HDL receptor SR-BI[J]. Biochim Biophys Acta, 2002, 1583(2):141-150.
[6]
Rockey DC. Liver fibrosis reversion after suppression of hepatitis B virus[J]. Clin Liver Dis, 2016, 20(4):667-679.
[7]
吴钦梅,尤红.中国乙型病毒性肝炎肝硬化研究现状[J].中国病毒病杂志,2014(1): 7-10.
[8]
赵治凤,樊晋宇,张光谋.1400例肝硬化患者流行病学分析[J]. 中国卫生检验杂志,2016(3):414-415.
[9]
Gemery JM, Forauer AR, Silas AM, et al. Hypersplenism in liver disease and SLE revisited: current evidence supports an active rather than passive process[J]. BMC Hematol, 2016(16):3.
[10]
Endo Y, Ohta M, Shibata K, et al. Splenectomy for hypersplenism caused by adult T-cell leukemia: report of a case[J]. Surg Today, 2008, 38(12):1148-1151.
[11]
Poddar U, Shava U, Yachha SK, et al.β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children[J]. Hepatol Int, 2015, 9(3): 447-453.
[12]
Hu Q, Takeishi K, Yamashita Y, et al. Splenectomy followed by hepatectomy for hepatocellular carcinoma with hypersplenism and portal hypertension caused by macroglobulinemia[J]. Anticancer Res, 2015, 35(7): 4077-4081.
[13]
Nair H, Berzigotti A, Bosch J. Emerging therapies for portal hypertension in cirrhosis[J]. Expert Opin Emerg Drugs, 2016, 21(2):167-181.
[14]
李展翼,刘莹,刘宇,等.脾切除加贲门周围血管离断术对肝硬化合并脾功能亢进患者肝功能的影响[J/CD].中华肝脏外科手术学电子杂志,2014, 3(4): 235-237.
[15]
纪泛扑,黄娜,张澍,等.脾切除对丙型病毒性肝炎后肝硬化门静脉高压症患者细胞免疫功能的影响[J/CD].中华肝脏外科手术学电子杂志,2015, 4(4):232-236.
[16]
Prystupa A, Kiciński P, Sak J, et al. Proinflammatory cytokines (IL-1α, IL-6) and hepatocyte growth factor in patients with alcoholic liver cirrhosis[J]. Gastroenterol Res Pract, 2015:532615.
[17]
Ataseven H, Bahcecioglu IH, Kuzu N, et al. The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection[J]. Mediators Inflamm, 2006(4):78380.
[18]
Walusimbi MS, Dominguez KM, Sands JM, et al. Circulating cellular and humoral elements of immune function following splenic arterial embolisation or splenectomy in trauma patients[J]. Injury, 2012, 43(2):180-183.
[19]
Guo Y, Wu CZ, Liao Y, et al. The expression and significance of CD4+CD25+ CD127low/- regulatory T cells and Foxp3 in patients with portal hypertension and hypersplenism[J]. Hepatogastroenterology,2013, 60(123): 581-584.
[20]
Rezende-Neto JB, Petroianu A, Santana SK. Subtotal splenectomy and central splenorenal shunt for treatment of bleeding from Roux en Y jejunal loop varices secondary to portal hypertension[J]. Dig Dis Sci, 2008, 53(2): 539-543.
[21]
Guan YS, Hu Y. Clinical application of partial splenic embolization[J]. ScientificWorldJournal, 2014: 961345.
[1] 蚁淳, 袁冬生, 熊学军. 系统免疫炎症指数与骨密度降低和骨质疏松的关联[J/OL]. 中华关节外科杂志(电子版), 2024, 18(05): 609-617.
[2] 母德安, 李凯, 张志远, 张伟. 超微创器械辅助单孔腹腔镜下脾部分切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 14-14.
[3] 吴鹏, 许维, 王壮, 郑世海, 宋劲松. 隧道法行腹腔镜下脾切除术的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(03): 319-322.
[4] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[5] 贺健, 张骊, 王洪海, 蒋文涛. 肝移植术后脾功能亢进转归及治疗研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 310-314.
[6] 杨建辉, 段文斌, 马忠志, 卿宇豪. 腹腔镜下脾部分切除术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 314-314.
[7] 卓文锋, 曾桂芳, 杨思加, 赵家立, 邹宝嘉, 白子锐, 林恩, 李坚. 腹腔镜巨脾切除术:逐步打破的手术壁垒[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 783-788.
[8] 邢颖, 程石. 巨脾外科治疗现状与介入治疗序贯手术策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 253-258.
[9] 廖艳, 成伟. 腹腔镜技术在胰腺癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 259-264.
[10] 刘起帆, 蒋安. 肝硬化门静脉高压症门静脉压力无创测量进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 270-275.
[11] 杨竞, 周光文. 肝硬化门静脉高压症治疗后再出血危险因素分析及预测模型构建[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 296-301.
[12] 张宇, 余灵祥, 赵亮, 张宁, 赵德希, 刁广浩, 杨木易, 刘佳, 李鹏, 任辉. 利伐沙班在脾切除联合贲门周围血管离断术后门静脉血栓预防中的疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 195-199.
[13] 苏日顺, 卢逸, 庄宝鼎, 张译, 李彦杰, 徐见亮. 肝硬化脾亢脾切除术后门静脉血栓形成影响因素[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 39-44.
[14] 许英晨, 张红, 付建柱, 张立军, 计嘉军. 脾脉管瘤合并脾囊肿一例报告[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 93-95.
[15] 林文斌, 郑泽源, 郑文能, 郁毅刚. 外伤性脾破裂腹腔镜脾切除术患者中转开腹风险预测模型构建[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 619-623.
阅读次数
全文


摘要